Showing 4291-4300 of 5771 results for "".
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- Ocutrx Technologies Adds to its Surgical Visualization Suite with Scopetrx, a Wireless Laparoscopic Swivel Camerahttps://modernod.com/news/ocutrx-technologies-adds-to-its-surgical-visualization-suite-with-scopetrx-a-wireless-laparoscopic-swivel-camera/2478876/Ocutrx Technologies has announced that they are expanding from external visualization augmented reality (AR) and extended reality (XR) techniques to a first-of-class laparoscopic visualization key-hole instrument called “Scopetrx,” a wireless laparoscopic swivel camera tool. The instrument’s mobi
- Nicox’s US Licensee Eyevance Expands U.S. Promotion of Zerviate In Agreement with Hikmahttps://modernod.com/news/nicoxs-us-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma/2478867/Nicox announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion of Zerviate, indicated for the treatment of ocular itching associated with allergic conjunc
- Reichert Technologies Debuts New Website Designed to Improve Customer Experiencehttps://modernod.com/news/reichert-technologies-debuts-new-website-designed-to-improve-customer-experience/2478866/Reichert Technologies has announced the launch of a newly redesigned website with an improved user experience. The new website, available at the same address—reichert.com—features a s
- Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%https://modernod.com/news/akorn-receives-fda-approval-for-loteprednol-etabonate-ophthalmic-gel-0-5/2478864/Akorn announced that it received approval of its abbreviated new drug application (ANDA) from the FDA for loteprednol etabonate ophthalmic gel, 0.5%, which is indicated for the treatment of postoperative inflammation and pain following ocular surgery. “We are excited to launch yet an
- Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Monthshttps://modernod.com/news/new-phase-3-data-show-genentechs-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatment-to-up-to-4-months/2478862/Genentech announced detailed results from four phase 3 studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/Lytenava (Bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-reports-final-visit-for-last-patient-in-open-label-safety-study-for-ons-5010-lytenava-bevacizumab-vikg/2478861/Outlook Therapeutics announced that the last patient completed their final visit for the ongoing open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases (NORSE THREE). Two of the three planned clinical trials for the ONS-5010/Lytenava wet age
- Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophyhttps://modernod.com/news/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/2478856/Trefoil Therapeutics announced it has begun a phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial o
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet